Osteocalcin is not a marker of progress in multiple myeloma

European Journal of Haematology

Volumn 56, Issue 1-2, 1996, Pages 30-34

  Mejjad, O ^a,e   Le Loet X ^a   Basuyau, J P ^b   Menard J F ^a   Jego, P ^c   Grisot, Ch ^d   Daragon, A ^a   Grosbois, B ^c   Euller Ziegler, L ^d   Monconduit, M ^b  

^a UNIVERSITÉ DE ROUEN   (France)

^b Centre Becquerel   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

Bone histomorphometry; Disease progress; Multiple myeloma; Osteocalcin; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; OSTEOCALCIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

EID: 9044243403     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00289.x     Document Type: Article

References (29)

1. 10. 7-1989: 14.
2. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975: 36: 842-854.
3. MUNDY GR, IBBOTSON KJ, D'SOUZA SM. Tumor products and the hypercalcemia of malignancy. J Clin Invest 1985: 76: 391-394.
4. BATAILLE R, GRENIER J, SANY J. Beta2 microglobulin in myeloma; optimal use of staging, prognosis and treatment. Blood 1984: 62: 468-476.
5. KALTWASSER PH, SAUGER F, LE LOËT X, PASQUIS P, MONCONDUIT M, DESHAYES P. Intérêt du dosage de la bêta-2-microglobuline dans la surveillance des myélomes. A propos de 290 dosages. Rev Rhum 1982: 48: 359-363.
6. MUNDY GR, RAISZ IG, COOPER RA, SCHECHTER GP, SALMON SE. Evidence of the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974: 291: 1041-[!]10455.
7. BATAILLE R, CHAPPARD D, MARCELLI CH, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989: 7: 1909-1914.
8. BATAILLE R, DELMAS P, SANY J. Serum bone gla-protein in multiple myeloma. Cancer 1987: 59: 329-334.
9. VALENTIN-OPRAN A, CHARBON S, MEUNIER P, EDOUARD C, ARLOT M. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982: 52: 601-610.
10. HAUSCHKA PV, LIAN JB, GALLOP PM. Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci (USA) 1975: 72: 3925-3929.
11. PRICE PA, OTSUKA AS, POSER JW, KRISTAPONIS J, RAMAN N. Characterization of a gamma-carboxyglutamic acid containing protein from bone. Proc Natl Acad Sci (USA) 1976: 73: 1447-1451.
12. PRICE PA, PARTHEMORE JG, DEFTOS LG. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980: 66: 878-883.
13. PRICE PA, WILLIAMSON MK, LOTHRINGER JW. Origin of the vitamin-K dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 1981: 256: 12760-12766.
14. LIAN J, GURNBERG C. Basic science and pathology. Osteocalcin: biochemical considerations and clinical applications. Clin Orthop 1988: 226: 267-291.
15. BROWN JP, MALAVAL L, CHAPUY MC, DEMAS PD, EDOUARD C, MEUNIER JP. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984: i: 1091-1093.
16. SEBERT JL, RUIZ JC, FOURNIER A, et al. Plasma bone Gla-protein: assessment of its clinical value as an index of bone formation in hemodialized patients. Bone Mineral 1987: 2: 21-27.
17. BATAILLE R, DELMAS PD, CHAPPARD D, SANY J. Abnormal serum bone Gla-protein levels in Multiple Myeloma. Cancer 1990: 66: 167-172.
18. DURIE BGM, SALMON SE. Multiple myeloma, macroglobulinemia and monoclonal gammapathies. In: HOFFBRAND A, BRAIN MC, HIRSH J, eds. Recent Advances in Haematology. Churchill Livingstone: New York, 1977: 243.
19. PARFITT AM, DREZNER MK, GLORIEUX FH, et al. Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Min Res 1987: 2: 595-610.
20. GUNDBERG CM, MARKOWITZ ME, MIZRUCHI M, ROSEN JF. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 1985: 60: 736-739.
21. JOHANSEN JS, THOMSEN K, CHRISTIANSEN C. Plasma bone Gla-protein concentrations in healthy adults: dependence on sex, age and glomerular filtration. Scand J Clin Lab Invest 1987: 47: 345-350.
22. ORWOLL ES, DEFTOS LJ. Serum osteocalcin (BGP) levels in normal men: a longitudinal evaluation reveals an age-associated increase. J Bone Min Res 1990: 5: 259-262.
23. RUFFIE A, FOSSATS A, COLLE M. Valeurs normales de l'ostéocalcine sérique au cours de la vie. Ann Biol Clin 1989: 47: 629-634.
24. VANDERSCHRUEREN D, GEVERS G, RAYMAEKERS G, DEVOS P, DEQUEKER J. Sex and age-related changes in bone and serum osteocalcin. Calcif Tissue Int 1990: 46: 179-182.
25. NAKATSUKA K, MIKI T, NISHIZAWA Y, et al. Circulating bone Gla protein in end stage renal disease determined by newly developed two sites immunoradiometric assay. Contrib Nephrol 1991: 90: 147-154.
26. LUKERT BP, HIGGINS JC, STOSKOPF MM. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 1986: 62: 1056-1058.
27. GODSCHALK MF, DONS RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Min Res 1988: 3: 113-115.
28. MASTERS PW, JONES RG, PURVES DA, COOPER EH, COONEY JM. Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 1994: 40: 358-363.
29. CARLSON K, LJUNGHALL S, SIMONSSON B, SMEDMYR B. Serum osteocalcin concentrations in patients with multiple myeloma - correlation with disease stage and survival. J Int Med 1992: 231: 133-137.